Published Aug 12, 2026
Agomab Therapeutics H1 2026 Earnings: IPO-Funded Runway Into 2029 With FSCD and IPF Catalysts
In-depth research on AGMB covering the business overview, key financial moves, risk frame, and the bottom-line on what changed since the last report.
3,410 words15 min read
Read report